'On consolidated basis

Quarter ended June 2025 compared with Quarter ended June 2024.

Net sales (including other operating income) of Aurobindo Pharma has increased 3.98% to Rs 7868.14 crore.  Operating profit margin has declined from 21.40% to 20.37%, leading to 1.02% decline in operating profit to Rs 1,603.03 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 32.28% to 31.80%.   Purchase of finished goods cost rose from 8.90% to 10.13%.   Employee cost increased from 14.03% to 15.41%.   Other expenses fell from 23.59% to 22.54%.   

Other income fell 52.34% to Rs 105.3 crore.  PBIDT fell 7.18% to Rs 1708.33 crore.  Provision for interest fell 11.97% to Rs 97.75 crore.  

PBDT fell 6.87% to Rs 1610.58 crore.  Provision for depreciation rose 0.38% to Rs 405.7 crore.  

Profit before tax down 9.08% ...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026